All In Biotech

Drug Trial Radar · NCT06427395

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

A Multicenter, Open-Label, Extension Clinical Trial to Evaluate Safety and Efficacy of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis (PBC)

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

102

Actual

Start

Jul 16, 2024

Primary completion

Apr 18, 2027

Study completion Jul 18, 2027

Sponsor

Lead sponsor
Zydus Therapeutics Inc.Industry
Sponsor type
Industry
First posted
May 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Conditions

  • Primary Biliary Cholangitis

Interventions

  • Saroglitazar Magnesium 1 mgDrug

    Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in the open label extension program

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as assessed by CTCAE v5.0Time frame: From baseline to 24 Months/EOT

Locations

28 sites in 3 countries. Site status is shown where the registry gives one.

  • Zydus US013

    Los Angeles, California

  • Zydus US011

    Pasadena, California

  • Zydus US043

    Sacramento, California

  • Zydus US022

    Aurora, Colorado

  • Zydus US037

    New Haven, Connecticut

  • Zydus US027

    Jacksonville, Florida

  • Zydus US006

    Lakewood Rch, Florida

  • Zydus US005

    Miami, Florida

  • Zydus US020

    Marietta, Georgia

  • Zydus US001

    Indianapolis, Indiana

  • Zydus US035

    Rochester, New York

  • Zydus US002

    Charlotte, North Carolina

  • Zydus US042

    Houston, Texas

  • Zydus US031

    Murray, Utah

  • Zydus US016

    Charlottesville, Virginia

  • Zydus US039

    Richmond, Virginia

  • Zydus US033

    Seattle, Washington

  • Zydus AR001

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Zydus AR007

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Zydus AR006

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Zydus AR005

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Zydus AR003

    Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

  • Zydus AR004

    Pilar, Buenos Aires, Argentina

  • Zydus TR016

    Altındağ, Turkey (Türkiye)

  • Zydus TR004

    Ankara, Turkey (Türkiye)

  • Zydus TR005

    Bursa, Turkey (Türkiye)

  • Zydus TR017

    Cebeli, Turkey (Türkiye)

  • Zydus TR015

    Melikgazi, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.